Drug Profile
MEDI 7247
Alternative Names: MEDI-7247Latest Information Update: 02 Mar 2020
Price :
$50
*
At a glance
- Originator MedImmune
- Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Pyrroles
- Mechanism of Action DNA cross linking agents; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies; Solid tumours
Most Recent Events
- 26 Feb 2020 Discontinued - Phase-I for Haematological malignancies (Second-line therapy or greater) in France, South Korea and USA (IV) before February 2020 (AstraZeneca pipeline, February 2020)
- 26 Feb 2020 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) before February 2020 (AstraZeneca pipeline, February 2020)
- 03 Jan 2020 Medimmune completes a phase I trial in Haematological malignancies (Second-line therapy or greater) in France, South Korea and USA (NCT03106428)